[
  {
    "ts": null,
    "headline": "With 81% ownership of the shares, Amgen Inc. (NASDAQ:AMGN) is heavily dominated by institutional owners",
    "summary": "Key Insights Given the large stake in the stock by institutions, Amgen's stock price might be vulnerable to their...",
    "url": "https://finnhub.io/api/news?id=9d600bf8e2ce6111518b57964c1686bab69f2216b8b7fc08ea9a8ae0fbebb212",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756562414,
      "headline": "With 81% ownership of the shares, Amgen Inc. (NASDAQ:AMGN) is heavily dominated by institutional owners",
      "id": 136581270,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Key Insights Given the large stake in the stock by institutions, Amgen's stock price might be vulnerable to their...",
      "url": "https://finnhub.io/api/news?id=9d600bf8e2ce6111518b57964c1686bab69f2216b8b7fc08ea9a8ae0fbebb212"
    }
  },
  {
    "ts": null,
    "headline": "Does Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)?",
    "summary": "Royalty Pharma announced it has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for US$885 million upfront, with an option to purchase up to an additional US$65 million in royalties over the next 12 months. This transaction gives Royalty Pharma a share in the worldwide sales of Imdelltra, a newly approved therapy for small cell lung cancer with analyst projections of more than US$2.8 billion in annual sales by 2035. We'll examine how Royalty Pharma’s investment in...",
    "url": "https://finnhub.io/api/news?id=bf518a9abcc4cc8ec09f1c29c79f5c7c80993c42bef7e6c6457e2dd72263e28e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756548930,
      "headline": "Does Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)?",
      "id": 136580001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Royalty Pharma announced it has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for US$885 million upfront, with an option to purchase up to an additional US$65 million in royalties over the next 12 months. This transaction gives Royalty Pharma a share in the worldwide sales of Imdelltra, a newly approved therapy for small cell lung cancer with analyst projections of more than US$2.8 billion in annual sales by 2035. We'll examine how Royalty Pharma’s investment in...",
      "url": "https://finnhub.io/api/news?id=bf518a9abcc4cc8ec09f1c29c79f5c7c80993c42bef7e6c6457e2dd72263e28e"
    }
  }
]